Floatz logo

Personalized Neoantigen Mrna Tumor Vaccine

Advanced Malignant Solid Tumors

Stemirna TherapeuticsvaccineN/AActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
73/ 100

Competitive context

36 Active assets in the Advanced Malignant Solid Tumors cohort.

Asset / SponsorPhaseRating
Neratinib
Puma Biotechnology, Inc.
Phase 1/2B
TRASTUZUMAB
Puma Biotechnology, Inc.
Phase 1/2B
Vinorelbine
Puma Biotechnology, Inc.
Phase 1/2B
Capecitabine
Puma Biotechnology, Inc.
Phase 1/2B
Trastuzumab Emtansine
Puma Biotechnology, Inc.
Phase 1/2B

View all 50 →

Same molecule, other indications

Personalized Neoantigen Mrna Tumor Vaccine is also rated in:

Solid Tumor MalignanciesDormant
C
Indicative ·
36 / 100
View asset →
hepatocellular carcinomaDormant
D
Indicative ·
30 / 100
View asset →
esophageal squamous cell carcinomaDormant
D
Indicative ·
30 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →